Amylyx Pharmaceuticals, Inc. (AMLX)

Market Cap	1.36B
Revenue (ttm)	-249,000
Net Income (ttm)	-187.60M
Shares Out	106.67M
EPS (ttm)	-2.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,281,545
Open	11.97
Previous Close	11.96
Day's Range	11.97 - 13.10
52-Week Range	2.60 - 13.10
Beta	-0.44
Analysts	Strong Buy
Price Target	14.86 (+16.37%)
Earnings Date	Nov 6, 2025

About AMLX

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 7, 2022
• Employees: 123
• Stock Exchange: NASDAQ
• Ticker Symbol: AMLX
• Website: https://amylyx.com

Analyst Summary

According to 7 analysts, the average rating for AMLX stock is "Strong Buy." The 12-month stock price target is $14.86, which is an increase of 16.37% from the latest price.

Price Target

$14.86

(16.37% upside)

Analyst Consensus: Strong Buy